// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Effects of STN-DBS on axial and non-motor symptoms in patients with Parkinson’s disease: a prospective study (P1.8-032)

Yasmine Miguel - American Academy of Neurology (AAN) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

A Descriptive Nation-wide Survey of Laboratory Monitoring Practices of Multiple Sclerosis Clinicians in Canada (P1.2-097)

Aman Atwal - American Academy of Neurology (AAN) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

Emotional Expressions associated with Therapeutic Inertia in Multiple Sclerosis care (P1.2-095)

Gustavo Saposnik - American Academy of Neurology (AAN) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

Cost effectiveness of Fingolimod Compared to Interferon-β1a in the Management of Pediatric-Onset Multiple Sclerosis (POMS) in Canada (P1.2-106)

Hamid Reza Nakhaipour - American Academy of Neurology (AAN) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

Fingolimod

The Traffic Light System reduces Therapeutic Inertia in MS Care: results from a RCT (P1.2-096)

Gustavo Saposnik - American Academy of Neurology (AAN) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Interactions Between Brain Structures and Genetic Variants in Neurotransmitter Systems as Potential Biomarkers for Hallucinations and Delusions in Alzheimer’s Disease (P1.1-012)

Juweiriya Ahmed - American Academy of Neurology (AAN) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Therapeutic Inertia Correlates with the Level of Agreement on the Landscape of MS Treatments (P1.2-101)

Jiwon Oh - American Academy of Neurology (AAN) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

A Mouse Model of Meningeal Inflammation and Subpial Demyelination Identifies an IL-17-mediated Mechanism of Cortical Injury that is Inhibited by Siponimod Therapy (S12.002)

Lesley Ward - American Academy of Neurology (AAN) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Siponimod

Hoarding and Obsessive-Compulsive Behaviours in Frontotemporal Dementia: Clinical and Neuroanatomical Associations (S13.007)

Eric Mitchell - American Academy of Neurology (AAN) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Frontotemporal dementia

N/A

Assessing Post-Stroke Cardiac Dysfunction in the Insular Ischemic Stroke Rat Model (S22.009)

Victoria Jaremek - American Academy of Neurology (AAN) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Vasodilation dysfunction

endothelin-1

Neurology International Residents Videoconference and Exchange (NIRVE) (P2.6-043)

Sanskriti Sasikumar - American Academy of Neurology (AAN) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Methadone hydrochloride

Quantitative EEG Burst Suppression Ratio and Patient Outcome in Refractory Status Epilepticus (P2.5-020)

Neil Mehdiratta - American Academy of Neurology (AAN) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Epoch

Genetic Characterization and Prognosis of Adult Patients with Lennox-Gastaut Syndrome: A Prospective Case-Series Study (P2.5-011)

Robert De Santis - American Academy of Neurology (AAN) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Lennox Gastaut syndrome

N/A

STXBP1 is associated with bruxism in awake patients (P2.5-008)

Arezoo Rezazadeh - American Academy of Neurology (AAN) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Prospective, Open-Label Study Evaluating the Safety and Tolerability of Higher Infusion Rates of Intravenous Immunoglobulin in Patients with Chronic Inflammatory Demyelinating Polyneuropathy. Interim analyses. (P2.4-028)

Yue Jiang - American Academy of Neurology (AAN) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Inflammatory demyelinating polyneuropathy

IVIG

Axial Weakness as the Presenting Manifestation of Myopathy (P2.4-037)

Andrea Parks - American Academy of Neurology (AAN) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Cap myopathy

N/A

Low Dose Dantrolene Treatment Reduced Pain in Patients with Strongman Syndrome. (P2.4-044)

Ludivine Chamard Witkowski - American Academy of Neurology (AAN) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Dantrolene Injection

Effect of Fumarates on Human iPSC Derived Neural Progenitor Cells and Human Primary Neurons (P2.2-054)

Maryam Nakhaei-Nejad - American Academy of Neurology (AAN) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Neuronal injury

N/A

AGED RATS HAVE AN ALTERED IMMUNE RESPONSE AND WORSE OUTCOMES AFTER TRAUMATIC BRAIN INJURY

Mujun Sun - National Neurotrauma Society (NNS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Traumatic brain injury

N/A

CHIMERA REPETITIVE MILD TBI INDUCES PTSDâ€LIKE BEHAVIOR AND CHRONIC NEUROPATHOLOGIES IN WILDâ€TYPE AND APP/PS1 MICE

Wai Hang Cheng - National Neurotrauma Society (NNS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Aducanumab

Copyright © 2026. QuantiNova All rights reserved